In line with our primary LGLL patient data, total ROS was significantly increased from 0.023% (control) to 9.6% (IL-6), 20.8% (IL-15), 7.2% (MCP-1), and 30.0% (IL-15 plus MCP1) (Fig. 5C). Here, IL6 is linked to T-cell large granular lymphocyte leukemia.